Abstract: Ultra-light oil texture cosmetic compositions suitable for being applied on the facial skin are provided. The compositions are used in the treatment and prevention of cutaneous stress and signs of extrinsic aging, particularly caused by external pollution aggressors.

Abstract: A dextrin fatty acid ester is provided in which the dextrin has an average degree of glycopolymerization of 3 or more and 100 or less. The fatty acid comprises one or more linear saturated fatty acids having 14 or more and 18 or less carbon atoms, and one or more branched saturated fatty acids having 14 or more and 18 or less carbon atoms. The molar fraction of the linear saturated fatty acid in the fatty acid is 0.75 or more and 0.95 or less. The average degree of substitution of the fatty acid per glucose unit is 1.5 or more and 2.0 or less.

Abstract: The present disclosure relates to cosmetic cleaning agents which, based in each case on their weight, contain from about 1 to about 30% by weight of surfactant(s); from about 0.1 to about 5% by weight of guaran (INCI name Guar Gum); from about 0.1 to about 5% by weight of xanthan (INCI name Xanthan Gum); from 0 to about 10% by weight of unmodified starch, from 0 to about 10% by weight of modified starch(es), with the proviso that the total amount of the two latter ingredients is from about 0.1 to about 10% by weight.

Abstract: The subject of the present invention relates to a composition for dyeing keratin fibers, comprising: a)one or more copolymer(s) derived from the polymerization of at least one monomer of crotonic acid or crotonic acid derivative and of at least one vinyl ester monomer, b)at least one oil-in-water emulsion having a particle size D 50 of less than 350 nm and which comprises: a silicone mixture comprising (i) at least one polydialkylsiloxane comprising trialkylsilyl end groups, having a viscosity at 25° C. ranging from 40 000 to 100 000 mPa·s and (ii) at least one aminosilicone having aviscosity at 25° C. ranging from 1000 to 15 000 mPa·s and an amine number ranging from 2 to 10 mg of KOH per gram of aminosilicone; a surfactant mixture comprising one or more nonionic surfactants, said mixture having an HLB ranging from 10 to 16, and water and c) at least one pigment.

Abstract: A cosmetic is provided, including a component (R): synthetic rubber particles, and a component (P): a polymer having a repeating unit (u1) represented by General Formula (p1). In General Formula (p1), R01, R02 and R03 each independently represents an alkyl group or a hydrogen atom; np represents an integer of 1 to 4; R10 represents a substituent; and mp represents an integer of 0 to (np+1).

Abstract: A robust sunscreen composition is disclosed herein comprising a water soluble polymer and a water insoluble film former providing a synergistic effect in SPF retention and critical wavelength after immersion in water, salt water, and chlorinated water. The water soluble polymer comprises poloxamer 338 (and) PPG-12/SMDI copolymer, poloxamer 407 (and) PPG-12/SMDI copolymer, or a combination thereof.

Abstract: The present disclosure is related to a method of treating and concealing a skin defect in a subject. The method comprises applying a makeup composition to the skin defect, wherein the makeup composition comprises silicone and a coloring agent, wherein the makeup composition simultaneously conceals and treats said skin defect. Makeup compositions and kits for treating and concealing skin defects are also disclosed.

Abstract: This invention relates to the use of polycarboxylic acid compounds, aqueous compositions comprising the same, cosmetic compositions comprising the same, in particular, hair care compositions, and their use for the treatment of hair, and a process for the treatment of hair comprising the use of said cosmetic compositions.

Abstract: Described herein is a method of conditioning the hair, the method including providing a hair care composition, adding a hydrofluoropropene to the hair care composition at a concentrated hair care composition to hydrofluoropropene weight ratio of from about 85:15 to about 98:2 to create a pressurized hair care composition, dispensing the pressurized hair care composition from an aerosol dispenser as a foam, applying the foam to the hair, and rinsing the foam from the hair. The hair care composition includes from about 0.5% to about 18% silicone, less than 8% high melting point fatty compound, and less than 5% cationic surfactant. The hair care composition has a viscosity of from about 1 centipoise to about 15,000 centipoise. The hair care composition has a high melting point fatty compound to silicone weight ratio of from about 0 to about 50:50.

Abstract: A lip scrub composition including an emollient, a botanical, an exfoliator, the exfoliator comprising Oryza Sativa Rice Powder and Citrus Limon Peel Powder, and a lip plumper, the lip plumper comprising Sodium Hyaluronate, Arnica Montana Flower Extract and Phytonadione.

Abstract: Disclosed is a topical composition comprising: (i) a first extract comprising botanical actives extracted from Rubia cordifolia; and, (ii) a second extract comprising volatile botanical actives extracted from Camellia sinensis, wherein said second extract comprises E-2-hexenal and linalool at ratio of 0.1:1 to 10:1 parts by weight. The cosmetic composition is useful for upregulation of at N a marker associated with differentiation of keratinocytes to provide epidermal skin barrier benefits.

Abstract: Disclosed is a method of applying a topical skin composition to skin. The method can include applying the composition to skin. The composition can include Silybum marianum fruit extract and Momordica grosvenorii fruit extract.

Abstract: The present disclosure relates to a cosmetic agent for temporarily reshaping keratin fibres. The cosmetic agent includes, a cosmetic carrier, a film former, and a natural thickener. The natural thickener includes carrageenan and/or salts thereof. The film former includes a hydroxypropyl group-modified starch compound.

Abstract: Provided is a natural shampoo composition containing a white dandelion extract solution, and more particularly, to a natural shampoo composition containing a white dandelion extract solution, a Portulaca oleracea L. extract and a red ginseng which has excellent washing effect and hair loss prevention effect and hair growth promotion effect.

Abstract: A method of preparing a skin treatment that includes preparing an extract of Arnica montana by mixing Arnica montana with ethyl alcohol, and filtering out the solids thereby resulting in liquid Arnica montana extract. In a first dilution, diluting the liquid Arnica montana extract with distilled water resulting in a first diluted Arnica montana extract. In a second dilution, diluting the first diluted Arnica montana extract with alkaline water resulting in a liquid skin treatment.

Abstract: Provided is a soothing cream including a skin conditioner, a solvent, a humectant, a viscosity increasing agent, a surfactant, a preservative, a chelating agent, and perfume, in which the skin conditioner includes a Maca root extract, a natural extract, niacinamide, glyceryl acrylate/acrylic acid copolymer, hyaluronic acid, arginine, hydrolyzed collagen, sucrose distearate, hydrogenated lecithin, and dimethicone.

Abstract: The precise trigger mechanisms for the initiation of Alzheimer's Disease (AD) remain unidentified. However, disturbances to the balance of thyroid hormone begin in the pre-clinical stage of Alzheimer's disease. Key elements of molecular pathology in AD can be correlated with a paucity of thyroid hormone activity in the brain. A method for reversing and/or slowing progression of AD and a method for formulation of a therapeutic agent for AD are presented herein wherein an active form of thyroid hormone, T3, is formulated into an extended release dose and administered to a patient safely normalizing key elements of molecular pathology of Alzheimer's Disease.

Abstract: The present disclosure is directed to oral vaccine dosage forms and processes for producing the oral vaccine dosage forms. The dosage forms include lipid-based vesicles (e.g., virosomes, liposomes) harboring an immunogenic amount of at least one vaccinal target molecule, with or without adjuvant. Specifically, Applicants discovered a combination of the composition of the liquid virosome concentrates, the composition of the base matrix for the solid dosage form formulation (excluding the virosome concentrate), and the manufacturing conditions for the dosage forms that can produce a freeze dried sublingual dosage form having physical robustness, particle and antigen integrity and stability.

Abstract: Nanoparticles including tacrolimus, and a method for providing nanoparticles including tacrolimus as well as to nanoparticles including tacrolimus that are obtainable by said method. Also relates to the nanoparticles including tacrolimus for use as a medicament. Further relates to a mucoadhesive buccal film containing the nanoparticles including tacrolimus and the mucoadhesive buccal film for use as a medicament, especially in pediatric patients.

Abstract: An effervescent tablet that exhibits rapid disintegration is disclosed. The effervescent tablet includes an effervescent agent that includes an acid and a base, a crystalline sugar binder selected from the group consisting of crystalline dextrose, crystalline sucrose, crystalline fructose, and combinations thereof, the crystalline sugar binder being essentially free of excipients, a sweetener that includes at least one of Stevia and Monk fruit, a flavor agent that includes a gum Arabic carrier, and optionally a lubricant derived from rice hulls (e.g., a multi-component integral lubricant).

Abstract: An effervescent tablet that exhibits rapid disintegration is disclosed. The effervescent tablet includes an effervescent agent that includes an acid and a base, a directly compressible sugar binder, a sweetener that includes at least one of Stevia and Monk fruit, a flavor agent that includes a gum Arabic carrier, and a lubricant derived from rice hulls.

Abstract: This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor.

Abstract: A composition intended for the remodelling treatment of a scar, by means of topical application, in particular, as a massage adjuvant. The composition takes the form of a microemulsion, preferably with a gel texture, containing a lipophilic compound, a wound healing agent, a humectant and an emulsifying agent, as well as a small amount of water.

Abstract: A method of treating osteoarthritis by modifying the shape change of bone(s) underlying articular cartilage, comprising evaluating the bone shape of the patient's joint, injecting the patient with a peptide of SEQ ID No. 1 or applying other therapeutic interventions that can reduce the shape change of the bone(s) underlying articular cartilage, and thereafter evaluating the bone shape of the patient's joint is disclosed.

Abstract: The invention provides a microneedle array easily applied to an oral cavity and may exert an anesthetic effect according to an application site. Provided are an immediate-acting dental local anesthetic preparation including a microneedle array containing a local anesthetic, in which a needle part dissolves in a mucous membrane when being applied to an oral mucous membrane or gums, the microneedle array containing the local anesthetic, in which a height of a microneedle is 50 ?m or more and 300 ?m or less, a rip of the microneedle is a circle having a diameter of 1 ?m or more and 50 ?m or less or a plane having the same area, and a thickness of a substrate of the microneedle array is 5 ?m or more and 100 ?m or less, and a microneedle patch including the microneedle array and a support provided on a back surface of the microneedle array.

Abstract: Described herein is a solid comprising (Z)-7-((1R,2R,3R,5S)-2-((S,E)-5-(2,5-dichlorothiophen-3-yl)-3-hydroxypent-1-en-1-yl)-3,5-dihydroxycyclopentyl)hept-5-enamide (hereinafter “Compound 1”) and ?-cyclodextrin, and preparations and uses thereof. Also described herein are certain solid forms, preparations and uses thereof.

Abstract: The present invention provides an oral care composition which includes one or more nonpolar structuring agents, one or more emulsifiers, one or more mucoadhesive polymers, and one or more active ingredients effective for providing oral pain relief. The oral care composition can be a solid or semi-solid composition up to a temperature of at least 40° C. Methods of providing such an oral care composition are also provided herein.

Abstract: Disclosed is a dry powder oral formulation that includes an active pharmaceutical ingredient (API), a lecithin powder, a galactomannan, one or more sweetening agents, one or more flavoring agents and an organic acid in a pharmaceutically acceptable preparation. Also disclosed are an excipient composition in absence of an API and methods of making and using the formulations and compositions. Also disclosed is a chewable, swallowable, and/or orally disintegrating tablet comprising an active pharmaceutical ingredient (API), a lecithin powder, a galactomannan, one or more sweetening agents, one or more flavoring agents and an organic acid in a pharmaceutically acceptable preparation.

Abstract: Water-soluble formulations including cannabinoids or a cannabis-derived compound for use in beverages and foods, methods of preparing the formulations, and methods of preparing beverages and foods including the formulations are disclosed herein. In other embodiments are provided water-soluble formulations that are physically and chemically stable, transparent or translucent in colour, calorie-free, and have minimal flavour.

Abstract: The application relates to an aqueous pharmaceutical formulation for use in the treatment of Type I or Type II Diabetes Mellitus, wherein the treatment reduces the risk of nocturnal hypoglycemia, said formulation comprising 200-1000 U/mL [equimolar to 200-1000 IU human insulin] of insulin glargine, with the proviso that the concentration of said formulation is not 684 U/mL of insulin glargine.

Abstract: Provided herein are nanoparticle-lipid composite carriers as theranostic agents, particularly for diagnosis and/or treatment of cancers and related diseases and conditions. In particular embodiments, the carrier composites comprise a lipid core and an outer shell of functionalized nanoparticles (fNPs).

Abstract: The invention relates to uses of an alcohol-free cosmetic or pharmaceutical foam carrier comprising water, a hydrophobic solvent, a foam adjuvant agent, a surface-active agent and a water gelling agent as a flame retardant or flame resistant foam. The hydrophobic solvent is preferably mineral oil; medium chain triglycerides; isopropyl myristearate or octyl dodecanol, silicone oil or vegetable oil or mixtures thereof. The cosmetic or pharmaceutical foam carrier does not contain aliphatic alcohols, also making it non-irritating and non-drying. The alcohol-free foam carrier is suitable for inclusion of both water-soluble and oil-soluble pharmaceutical and cosmetic agents.

Abstract: The present invention provides a pharmaceutical composition for the lubrication of joints, the pharmaceutical composition comprising a non-ionic tonicity agent comprising a polyol, and liposomes comprising at least one membrane comprising at least one phospholipid (PL) selected from a glycerophospholipid (GPL), said GPL having two C12-C18 hydrocarbon chains, being the same or different, and sphingomyelin (SM) having a C12-C18 hydrocarbon chain, the pharmaceutical composition being essentially free of an additional pharmaceutically active agent, wherein the at least one membrane has a phase transition temperature in the range of about 20° C. to about 39° C. and the joint has a joint temperature which is above the phase transition temperature.

Abstract: The present invention relates to a method for preparing a protocell in form of a giant unilamellar vesicle, which comprises the following steps: a) providing a water-based droplet encapsulated by an outer polymer shell, which borders the inner space of the droplet, wherein the droplet has a maximum dimension of 0.5 ?m to 1,000 ?m, wherein the inner space of the droplet contains at least one lipid, b) transforming the lipid content of the droplet into a lipid bilayer which is arranged at and covers the inner surface of the polymer shell and oil phase in order to form a polymer shell-stabilized giant unilamellar vesicle, c) optionally incorporating one or more proteins and/or nuclei into the polymer shell-stabilized giant unilamellar vesicle provided in step b) and d) optionally removing the polymer shell and oil phase from the polymer shell-stabilized giant unilamellar vesicle and optionally transferring it from the oil to the water phase.

Abstract: Cannabis and cannabis-derived compositions, methods of making and methods of using the compositions in oral dosage forms, such as in beverage forms, are disclosed herein. The compositions comprise a cannabinoid or a cannabis-derived compound, inulin and pectin and may be in powder or liquid form.

Abstract: The present invention relates to nano-resin particles that are suitable for pharmaceutical use and their use in the pharmaceutical field. The present invention provides nano-sized resin particles having a particle size distribution characterized in that D90 value is between 200 nanometers to 900 nanometer and D10 value is not less than 50 nanometers, wherein the nano-resin particles are in pure form and safe for pharmaceutical use. The present invention further relates to pharmaceutical compositions comprising these purified nano-resin particles and their use in the treatment of diseases.

Abstract: A preparation comprised of one or more pellets having an outer shell and core. The outer shell is made of dissolvable material and said core containing poly (ethylene glycol).

Abstract: Freeze dried active compositions are described. The compositions comprise less than 6.5% by weight water and they may be hydrated or added to end use compositions in order to yield compositions for delivering superior topical benefits to consumers.

Abstract: The present invention relates to a solid extended release pharmaceutical dosage form, comprising a mixture in the form of an extended release matrix formulation, the mixture comprising at least: (1) at least one poly(e-caprolactone), and (2) at least one polyethylene oxide, and (3) at least one active agent.

Abstract: An object of the present invention is to provide a pharmaceutical tablet having high tensile strength and excellent in immediate disintegrability. The pharmaceutical tablet of the present invention is obtained by a direct compression method, and contains an active ingredient, a polyvinyl alcohol resin, and a plasticizer other than water, wherein a content of the plasticizer is 1 to 8 parts by weight with respect to 100 parts by weight of the polyvinyl alcohol resin.

Abstract: The present invention relates to the therapeutic uses of compositions containing antibody molecules and functional fragments thereof e.g antibody molecules and functional fragments capable of binding to tumor necrosis factor alpha (TNF?), in the topical treatment of inflammatory bowel diseases, including Crohn's disease and ulcerative colitis.

Abstract: The present disclosure provides solid solution capsule formulations of Compound 1 and methods of making the same. Also provided herein are methods of treating individuals suffering from or susceptible to a disease or disorder involving pathologic activation of C5a receptors by administering an effective amount of one or more solid solution capsules comprising Compound 1. Further provided herein are singe unit dosage capsules comprising certain amounts of Compound 1, and kits comprising a solid solution capsule comprising Compound 1.

Abstract: Disclosed are compositions and methods for the co-delivery of ribonucleic acids and interferon binding proteins. Compositions include mineral coated microparticles having a mineral layer, a ribonucleic acid, and an interferon binding protein. Ribonucleic acids and interferon binding proteins can be adsorbed to the mineral layer, can be incorporated into the mineral layer, and combinations thereof. Also disclosed are methods for co-delivery of ribonucleic acids and interferon binding proteins and methods for treating inflammatory diseases using mineral coated microparticles having a mineral layer to provide co-delivery of ribonucleic acids and interferon binding proteins.

Abstract: A composition comprising a core material, having a taste value and a polymeric coating. The polymeric coating substantially surrounds the core material and comprises a cationic polymer and optionally an anionic polymer. The polymeric coating has a uniform thickness ranging from 2 ?m to 20 ?m. The composition provides release of a portion of the core material which is taste masked over a time period ranging from 0.5 minute to 2 minutes in the oral cavity and provides a modified-release of the remaining core material in a gastrointestinal tract.

Abstract: The invention provides a nanoparticle composition that is decorated with a urea-based small-molecule peptidomimetic inhibitor of prostate specific membrane antigen (PSMA), which is expressed by almost all solid tumors. This strategy takes advantage of both the avidity of the functionalized nanoparticle for binding to PSMA and the ability of the nanoparticle to be retained for longer periods of time in the tumor due to enhanced leakage via EPR into the tumor interstitium and poor clearance due to underdeveloped or non-existent lymphatics within the tumor.

Abstract: The present invention provides for a method of treating a disease such as cancer, comprising the step of administering to a patient a therapeutically effective amount of an isomer or analog of monoterpene or sesquiterpene (or its derivative), such as an isoperillyl alcohol. The present invention also provides for a method of treating a disease comprising the step of administering to a patient a therapeutically effective amount of a derivative of an isomer or analog of monoterpene or sesquiterpene, such as an isoperillyl alcohol carbamate. The derivative may be an isoperillyl alcohol conjugated with a therapeutic agent such as a chemotherapeutic agent. The route of administration may vary, including inhalation, intranasal, oral, transdermal, intravenous, subcutaneous or intramuscular injection.

Abstract: A nasally administered cannabinoid semi-solid or viscous liquid composition; nasal methods for administering the nasal pharmaceutical compositions; methods for manufacturing the nasal pharmaceutical compositions; and nasal methods of treating diseases treatable by the nasal pharmaceutical compositions formulated with a cannabinoid or mixtures thereof.

Abstract: A pharmaceutical composition, and methods for using a pharmaceutical composition, for treating osteoarthritis in a subject in need thereof, the pharmaceutical composition including cannabidiol or a pharmaceutically acceptable salt thereof; and especially wherein administration of the cannabidiol is by a transdermal pharmaceutical gel composition. A method is disclosed for treating one or more symptoms of osteoarthritis in a patient. The method includes transdermally administering an effective amount of cannabidiol (CBD) to the patient wherein one or more symptoms of osteoarthritis are treated in the patient.

Abstract: The present invention relates to a composition comprising ethyl vanillin or a pharmaceutically acceptable salt thereof as an effective ingredient for preventing or treating muscle disease or for improving a muscle function. Having the capability of upregulating the expression of a protein associated with muscle protein synthesis and muscle mass increase in myocytes and downregulating at an mRNA level the expression of an enzyme involved in muscle protein degradation, ethyl vanillin can exhibit effects of muscle differentiation, muscle regeneration, and muscle strengthening through an increase in muscle mass against muscle diseases attributed to muscle function decrease, muscle consumption, or muscle degradation and can suppress sarcopenia. Thus, ethyl vanillin can be used for preventing or treating muscle diseases or for promoting muscle differentiation, muscle regeneration and muscle strengthening, muscle mass increase, or muscle generation or for improving muscle function.

Abstract: A method of treating and/or preventing symptoms of Doose syndrome in a patient such as a patient previously diagnosed with Doose syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Doose syndrome patients are treated at a preferred dose of less than about 10.0 to about 0.01 mg/kg/day.